Saturday, July 30, 2016 9:53:14 PM
My current longs are just CDXC, LGND, NVDA, COST, ROST, TJX. (Besides, I hold ETFs IBB and ITB.) I'm reducing them (except CDXC) as their share prices increases. Other than that, I'm mainly doing short-term short-side trades, close to be day trading. If you have great short ideas please send them to me. I also have plenty of cash at this point.
On CDXC, I'm expecting a decent Q2. I have posted what I called expectation for a ho-hum quarter. However, beneath the surface, that kind of ho-hum result is actually a bit exciting.
Ex. special interest charges:
EPS = $0.009 to $0.014
With reasonable assumption about stock based comp and D&A expenses, here are the corresponding adjusted EBITDA
Adj. EBITDA = $1.27 million to $1.47 million.
QoQ growth = 45% to 68%
YoY growth = 213% to 264%
1H YoY growth = 635% to 705%
Management should emphasize the QoQ and YoY growth rate on EBITDA, if the result turns out to be within or near this range. Quite impressive actually, as you can see. If presented this way, the stock should be able to break out above its 200 and 50 EMA quickly.
I also have a blow-out scenario:
Ex. special interest charges:
EPS = $0.025
Adj. EBITDA = $1.90 million
QoQ growth = 117%
YoY growth = 369%
1H YoY growth = 852%
Management should again highlight adjusted EBITDA growth rate.
I believe institutional investors should have been crunching numbers at least just as we are doing. So, the blow-out case would send stock rallying 30-50% in days or weeks. I do not count on this blow-out scenario though. Stars have to be all aligned right for this to happen.
Turning to a less upbeat topic, the largest shareholder (Dr. Frost) of CDXC reduced a total of 1.378 million shares. His ownership is now about 9.8%, although his latest SC 13D/A filing indicated 10.47% as of June 21.
The market rightly shrugged the news off. Basically, Dr. Frost has been reducing his holding in other companies to fund share purchases in his own company, OPK, and to a much less extent, one (IDC) he is a Vice Executive Chairman. He is NOT a director with CDXC. He is just a large shareholder.
Just in case you need to have the knowledge. (The more you know the better, of course.)
You all have a nice weekend too.
Recent CDXC News
- ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 • Business Wire • 05/23/2024 12:34:00 PM
- ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award • Business Wire • 05/22/2024 12:32:00 PM
- ChromaDex Corporation Reports First Quarter 2024 Financial Results • Business Wire • 05/08/2024 08:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:02:02 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:01:05 PM
- ChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement • Business Wire • 04/30/2024 12:32:00 PM
- ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe® • Business Wire • 04/25/2024 12:34:00 PM
- ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 • Business Wire • 04/24/2024 12:34:00 PM
- ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market • Business Wire • 04/23/2024 12:32:00 PM
- ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program • Business Wire • 03/26/2024 12:32:00 PM
- ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results • Business Wire • 03/06/2024 09:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:02:29 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 09:01:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2024 02:00:40 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2024 01:59:47 AM
- ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024 • Business Wire • 02/21/2024 01:32:00 PM
- ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024 • Business Wire • 02/05/2024 01:32:00 PM
- ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference • Business Wire • 01/26/2024 09:08:00 PM
- ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen® • Business Wire • 12/20/2023 02:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 09:00:16 PM
- Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+ • PR Newswire (US) • 12/12/2023 03:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/04/2023 09:12:33 PM
- A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD) • Business Wire • 11/30/2023 01:34:00 PM
- Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients • Business Wire • 11/15/2023 01:32:00 PM
- ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023 • Business Wire • 11/09/2023 01:32:00 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM